72 197

Cited 0 times in

Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study

DC Field Value Language
dc.contributor.author박준용-
dc.contributor.author김승업-
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author전미영-
dc.contributor.author한광협-
dc.contributor.author안상훈-
dc.date.accessioned2020-09-29T05:31:36Z-
dc.date.available2020-09-29T05:31:36Z-
dc.date.issued2020-07-
dc.identifier.issn1976-2283-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/179549-
dc.description.abstractBackground/aims: Prognostic models are lacking for patients with recurrent hepatocellular carcinoma (HCC) following surgical resection. This study devised and validated a new hepatoma arterial-embolization prognostic (HAP) score optimized for use in patients undergoing treatment with transarterial chemoembolization (TACE) for recurrence subsequent to surgical resection of HCC. Methods: Training cohort (n=424) and validation cohort (n=350) patients with recurrent HCC after resection treated with TACE between 2003 and 2016 were enrolled. Cox regression and area under the receiver operating characteristic curve (AUC) analyses were used to identify risk factors for survival and to calculate the predictive performance of risk scores, respectively. Results: The median age of the study population was 59.2 years. α-Fetoprotein >400 ng/mL (hazard ratio [HR]=1.815), serum albumin ≤3.5 g/dL (HR=1.966), tumor number ≥2 (HR=1.425), tumor size >5 cm at resection or recurrence (HR=1.356), segmental portal vein invasion at resection or recurrence (HR=2.032), and time from resection to recurrence ≤1 years (HR=1.849) independently predicted survival (all p<0.05). The postoperative HAP (pHAP) model based on the rounded HRs of these variables showed an AUC of 0.723 for predicting survival at 3 years, which was significantly higher than AUCs of other HAP-based models, including HAP, modified HAP, and modified HAP-II scores (0.578-0.621) (all p<0.05). The accuracy of pHAP was maintained in the entire cohort (n=774; AUC=0.776 at 3 years). Conclusions: A new pHAP score optimized for patients treated with TACE due to recurrent HCC after resection showed acceptable accuracy and was externally validated. Further studies of means by which to select treatment options other than TACE for high-risk patients according to pHAP scores are warranted.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherEditorial Office of Gut and Liver-
dc.relation.isPartOfGUT AND LIVER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleProposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorMi Young Jeon-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorJeong-Hoon Lee-
dc.contributor.googleauthorSu Jong Yu-
dc.contributor.googleauthorYoon Jun Kim-
dc.contributor.googleauthorJung-Hwan Yoon-
dc.contributor.googleauthorEun Ju Cho-
dc.contributor.googleauthorSeung Up Kim-
dc.identifier.doi10.5009/gnl19111-
dc.contributor.localIdA01675-
dc.contributor.localIdA00654-
dc.contributor.localIdA00654-
dc.contributor.localIdA00385-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00487-
dc.contributor.localIdA05405-
dc.contributor.localIdA05405-
dc.contributor.localIdA04268-
dc.contributor.localIdA04268-
dc.contributor.localIdA02226-
dc.contributor.localIdA02226-
dc.relation.journalcodeJ00954-
dc.identifier.eissn2005-1212-
dc.identifier.pmid31640304-
dc.subject.keywordCarcinoma-
dc.subject.keywordChemoembolization-
dc.subject.keywordRecurrence-
dc.subject.keywordSurgery-
dc.subject.keywordhepatocellular-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor전미영-
dc.contributor.affiliatedAuthor전미영-
dc.contributor.affiliatedAuthor한광협-
dc.contributor.affiliatedAuthor한광협-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor안상훈-
dc.citation.volume14-
dc.citation.number4-
dc.citation.startPage477-
dc.citation.endPage485-
dc.identifier.bibliographicCitationGUT AND LIVER, Vol.14(4) : 477-485, 2020-07-
dc.identifier.rimsid67157-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.